No Data
Runben Biotechnology (SHSE:603193) May Have Issues Allocating Its Capital
Runben Co., Ltd. (603193.SH): JNRY VIII has collectively reduced its Shareholding by 3%.
On February 10th, Gelonghui reported that Runben Co., Ltd. (603193.SH) announced that on February 10, 2025, the company received a notification letter regarding the implementation results of the Shareholding plan from JNRY VIII. The number of shares sold by the reducing Shareholder has reached the number stated in the announcement of the shareholding plan, and this reducing plan has been completed. During the selling period, JNRY VIII reduced its holdings of the company's shares by a total of 4,045,900 shares through centralized bidding, accounting for 1.00% of the total shares of the company; and through block trading, a total of 8,091,866 shares were reduced, accounting for 2.00% of the total shares of the company.
Runben Biotechnology Co., Ltd.'s (SHSE:603193) Stock Has Fared Decently: Is the Market Following Strong Financials?
Runben Co., Ltd.: 2024 performance forecast
2024 Annual Results Forecast
Runben Co., Ltd. (603193.SH): It is expected that net income will increase by 32.73% to 37.15% year-on-year in 2024.
On January 22, Gelonghui reported that Runben Co., Ltd. (603193.SH) announced, based on the preliminary calculations by the finance department, that it is expected to achieve a net income attributable to the owners of the parent company of 300 million to 310 million yuan for the year 2024, which represents an increase of 73.9729 million to 83.9729 million yuan compared to the same period last year, a year-on-year growth of 32.73% to 37.15%. It is expected that the net income attributable to the owners of the parent company, excluding non-recurring gains and losses, will be 288.7724 million to 298.7724 million yuan for the year 2024, which represents an increase of 7,0.